Carbohydrate-Derived Sepsis Drug Shows Promise in Phase II Trial
Griffith University researchers reported promising Phase II results for STC3141, a carbohydrate-based drug tested in 180 sepsis patients in China. The therapy aims to reverse organ damage by dampening a harmful inflammatory surge, rather than just treating symptoms. Grand Pharma plans a Phase III trial, with potential market a few years away.